PHASE I CLINICAL TRIAL OF TEMOZOLOMIDE AND METHOXYAMINE (TRC-102), AN INHIBITOR OF BASE EXCISION REPAIR, IN PATIENTS WITH ADVANCED SOLID TUMORS

PURPOSE: Temozolomide (TMZ) generates DNA adducts that are repaired by direct DNA and base excision repair mechanisms. Methoxyamine (MX, TRC-102) potentiates TMZ activity by binding to apurinic and apyrimidinic (AP) sites after removal of N(3)-methyladenine and N(7)-methylguanine, inhibiting site re...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Invest New Drugs
Autori principali: Eads, Jennifer R., Krishnamurthi, Smitha S., Saltzman, Joel, Bokar, Joseph A., Savvides, Panos, Meropol, Neal J., Gibbons, Joseph, Koon, Henry, Sharma, Neelesh, Rogers, Lisa, Pink, John J., Xu, Yan, Beumer, Jan H., Riendeau, John, Fu, Pingfu, Gerson, Stanton L., Dowlati, Afshin
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7744386/
https://ncbi.nlm.nih.gov/pubmed/32556884
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-020-00962-x
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi